Compounding pharmacies in Kansas

By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified Sep 22, 2026

The Kansas State Board of Pharmacy regulates compounding pharmacies in Kansas. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Kansas at a glance

Pharmacy regulator: Kansas State Board of Pharmacy
503A framework: Follows the federal 503A framework
Telehealth prescribing: Regulatory: Telehealth allowed
Asynchronous prescribing: Regulatory: Async unclear
Compounded GLP-1 access: Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Kansas

No verified compounding pharmacies serving Kansas are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Kansas

The Kansas State Board of Pharmacy regulates pharmacies under the Kansas Pharmacy Act (K.S.A. 65-1625 and following) and Board regulations in K.A.R. Article 68. Kansas has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). K.S.A. 65-1657 bars any nonresident pharmacy from shipping, mailing, or delivering prescription drugs or devices to a patient, a patient's agent, or a prescriber's office in Kansas unless it holds an annual Kansas nonresident pharmacy registration, and it prohibits unregistered pharmacies from advertising to Kansas residents. Covering shipments to prescribers' offices matters for clinics that order compounded peptides for in-office administration. Compounding standards are in K.A.R. Article 13 of the Board's regulations: 68-13-2 (definitions), 68-13-3 (nonsterile preparations), and 68-13-4 (sterile preparations), and 68-13-4 bars compounding a sterile preparation that is essentially a copy of a commercially available drug unless the prescriber documents a clinically significant difference for the individual patient or the drug is on the federal shortage list. House Bill 2068 (2026) adopts USP chapters 795, 797, and 825 under the Kansas Pharmacy Act effective July 1, 2027, and the Board is drafting matching amendments to Article 13. [1] [2] [3] [4] [6] [7]

Compounded GLP-1 access in Kansas

Kansas patients using telehealth GLP-1 programs should confirm the prescriber holds a Kansas license and that the dispensing pharmacy has a Kansas nonresident pharmacy registration under K.S.A. 65-1657. The Kansas Board of Pharmacy's statement on compounding and dispensing GLP-1 and GIP receptor agonists (last updated August 26, 2026) says semaglutide and tirzepatide are no longer in shortage, that no salt form of either may be used in a compounded drug, and that even when compounding is otherwise allowed, a non-pharmaceutical grade bulk substance or one not made in an FDA-registered establishment is prohibited. It also says pre-printed or check-box prescriptions may not document the patient-specific need that copies of approved drugs require, and that retatrutide and cagrilintide cannot be used to compound under federal law. [4] [6] [10] [11]

Research use only sellers in Kansas

K.S.A. 65-1657 bars unregistered nonresident pharmacies from shipping prescription drugs into Kansas and from advertising to Kansas residents. The Kansas Board of Pharmacy's GLP-1 statement adds that compounding pharmacies must use pharmaceutical-grade active ingredients, not research use, investigational, food, or supplement grade, with a certificate of analysis naming the original manufacturer, and that a pharmacist may not dispense a product compounded in a non-compliant manner. [4] [6] [12]

Kansas notes on specific peptides

Semaglutide: Available branded by prescription, including by telemedicine under the Kansas Telemedicine Act, which requires a report to your primary care physician within three business days when you consent. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [5] [10]

How to check a compounding pharmacy in Kansas

Search the Kansas State Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Kansas requires before it ships to you. [1] [2] [3] [4] [6] [7]
Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Kansas. [4] [6] [12]

Common questions in Kansas

What does an out-of-state pharmacy need to ship compounded peptides to Kansas?

A Kansas nonresident pharmacy registration under K.S.A. 65-1657, renewed annually. The law covers shipments to patients, their agents, and prescribers' offices, and unregistered pharmacies may not advertise to Kansas residents. [6]

Can a Kansas pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [8] [9]

All peptide legal questions for Kansas